Gilead Sciences Inc - Company Profile
Powered by 
All the sales intelligence you need on Gilead Sciences Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Gilead Sciences Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Gilead Sciences Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View moreBusiness Description
Gilead Sciences Inc (Gilead) is a biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for life-threatening diseases. The company operates in the virology, oncology, and inflammation therapeutic areas, with an emphasis on HIV, viral hepatitis, cancer, and inflammatory diseases.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Gilead is focused on the discovery and development of transformational therapies primarily targeting viral diseases, cancer, and inflammatory conditions. The company is advancing its R&D pipeline. The company is committed to internal R&D opportunities and external business development activities to drive innovation and growth. Gilead Sciences Inc extensively outsources clinical trial activities to third-party contract research organizations for most of its clinical studies. It is committed to advancing innovative therapies through its extensive research and development programs, aiming to deliver 10+ transformative therapies by 2030. The company leverages its expertise in virology, oncology, and immunology to develop next-generation therapies and is actively involved in both internal R&D opportunities and external business development activities. The R&D portfolio of Gilead includes 53 active clinical-stage programs in development across our core therapeutic areas. The R&D units are responsible for the discovery and development of new molecules and technologies, to obtain approval for innovative medicines and therapies. The company extensively outsources its clinical trial activities to third-party contract research organizations, which handle most of the clinical studies, including document preparation, site identification, screening, training, program management, patient enrollment, and bioanalysis. The company operates R&D centers in Oceanside and Santa Monica, California; Frederick, Maryland; Philadelphia, Pennsylvania; Edmonton, Canada; Dublin, Ireland; and Cambridge and Oxford, the UK. In FY2025, the company spent US$5,799 million on its R&D activities, which as a percentage of revenue, stood at 19.7%. As of December 2025, the company had 53 clinical-stage programs in its pipeline, with 25 in Phase I, 13 in Phase II, and 15 in Phase III. A few of the company's products in Phase III are Lenacapavir combinations, Axicabtagene ciloleucel, Anitocabtagene autoleucel, and Sacituzumab govitecan-hziy. In FY2025, the company also received approval from the US FDA to market Livdelzi for the treatment of PBC in combination with UDCA in adults, Trodelvy for the treatment of adult patients with extensive-stage small cell lung cancer, Biktarvy to treat people with HIV who have suppressed viral loads with known or suspected M184V/I resistance, and Vemlidy for the treatment for chronic HBV infection in paediatric patients of six years and above with minimum weight of 25 kilograms.
Product Categories
Overview
Includes the manufacturing and distribution of drugs related to the therapy area in HIV. Major brands include Biktarvy, Genvoya, Descovy, Odefsey, Complera /Eviplera, Symtuza, Truvada, Stribild, and Sunlenca. Biktarvy is an oral formulation for the treatment of HIV-1 infection in certain patients. Genvoya is an oral formulation for the treatment of HIV-1 infection in certain patients. Descovy is an oral formulation indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in certain patients. Odefsey is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. Complera /Eviplera is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. Symtuza is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. Truvada is an oral formulation indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in certain patients. Stribild is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. Sunlenca is an HIV-1 capsid inhibitor in tablet form for oral use and as an injection for subcutaneous use.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Include the manufacturing and distribution of drugs related to the therapy area in liver disease, including viral hepatitis such as HBV, HCV, HDV, and primary biliary cholangitis (PBC). Brands include Epclusa, Vemlidy, Harvoni, Viread, and Livdelzi. Epclusa is an oral formulation of sofosbuvir and velpatasvir for the treatment of chronic hepatitis C virus (HCV) Infection in adults and pediatric patients 3 years of age and older. Vemlidy is an oral formulation of TAF for the treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients 12 years of age and older with compensated liver disease. Harvoni is an oral formulation of a once-daily, single-tablet regimen of ledipasvir and sofosbuvir for the treatment of chronic HCV infection in adults and pediatric patients 3 years of age. Viread is an oral formulation of TDF for the treatment of chronic HBV infection in adults and pediatric patients 2 years of age and older and weighing at least 10 kg. Livdelzi is an oral formulation of a peroxisome proliferator-activated receptor delta agonist for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Includes the manufacturing and distribution of drugs related to the therapy area in Oncology, including Trodelvy for 2L+ mTNBC and pre-treated HR+/HER2- mBC; Yescarta for R/R 2L+ LBCL and accelerated approval for 3L R/R FL; and Tecartus for R/R adult ALL and accelerated approval for R/R MCL. Brands include Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Yescarta is a chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with large B-cell lymphoma; relapsed or refractory LBCL after two or more lines of systemic therapy; and relapsed or refractory FL after two or more lines of systemic therapy. Tecartusis a CAR T-cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma and relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Trodelvy is a Trop-2 directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least one of them for metastatic disease; and unresectable locally advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Includes the manufacturing and distribution of drugs related to the therapy areas of invasive fungal infection and the treatment of pulmonary arterial hypertension. Brands include AmBisome and Letairis. AmBisome is a proprietary liposomal formulation of amphotericin B, an antifungal agent, for the treatment of serious invasive fungal infections caused by various fungal species in adults. Letairis is an oral formulation of an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH) and improve exercise capacity and delay clinical worsening, or in combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Include other activities, including royalties for outbound licenses of our intellectual property and other payments received from our collaborations with third-party partners.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Offers an injection of a nucleotide analog RNA polymerase inhibitor through intravenous to treat COVID-19 in certain adults and pediatric patients aged 28 days of age and older and weighing at least 3 kg or who are hospitalized, not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death. Brand include Veklury.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Geographical Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer